Compound: Tedisamil
SMILES: N1(C[C@@H]2C3(CCCC3)[C@H](C1)CN(C2)CC4CC4)CC5CC5
InChIKey: CTIRHWCPXYGDGF-HDICACEKSA-N
Synonyms: Tedisamil, 90961-53-8, Tedisamilum, KC-8857, KC8857, 3,7-bis(cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclopentane], A5VAY2U3R8, 3',7'-Bis(cyclopropylmethyl)spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane), CHEBI:134747, DTXSID30238334, Spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane), 3',7'-bis(cyclopropylmethyl)-, 3,7-di-(cyclopropylmethyl)-9,9-tetramethylene-3,7-diazabicyclo(3.3.1)nonane, 3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane], 3,7-bis(cyclopropylmethyl)-3,7-diazaspiro(bicyclo(3.3.1)nonane-9,1'-cyclopentane), 3,7-bis(cyclopropylmethyl)spiro(3,7-diazabicyclo(3.3.1)nonane-9,1'-cyclopentane), RefChem:187699, C01BD06, DTXCID50160825, KC 8857, Tedisamil (USAN), TEDISAMIL [USAN], Tedisamil [INN], Tedisamilum [INN-Latin], UNII-A5VAY2U3R8, Tedisamil [USAN:INN:BAN], TEDISAMIL [MI], TEDISAMIL [MART.], TEDISAMIL [WHO-DD], SCHEMBL157918, CHEMBL113461, GTPL2567, orb1702743, SCHEMBL10025758, CTIRHWCPXYGDGF-UHFFFAOYSA-N, BDBM50088367, AKOS040746397, DB06200, CS-0106924, NS00068093, D06652, Q3982536, (1s,5s)-3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
Theoretical properties:
molecular_formula: C19H32N2
molecular_weight: 288.5 g/mol
exact_mass: 288.256549029 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 4
heavy_atom_count: 21
topological_polar_surface_area: 6.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Tedisamil is a member of the class of diazabicyclononanes that is (1s,5s)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] in which the hydrogens at positions 3 and 7 are replaced by cyclopropylmethyl groups. It is a potassium channel blocker and an antiarrhythmic agent currently currently in development for the treatment of atrial fibrillation. It has a role as an anti-arrhythmia drug and a potassium channel blocker. It is a diazabicyclononane, a member of cyclopentanes, an azaspiro compound and a member of cyclopropanes.
chebi: A member of the class of diazabicyclononanes that is (1<i>s</i>,5<i>s</i>)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] in which the hydrogens at positions 3 and 7 are replaced by cyclopropylmethyl groups. It is a potassium channel blocker and an antiarrhythmic agent currently currently in development for the treatment of atrial fibrillation.
wikipedia: Tedisamil (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III antiarrhythmic agent currently being investigated for the treatment of atrial fibrillation. Tedisamil blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of tedisamil have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria. Tedisamil is administered intravenously and has a half-life of approximately 8 –13 hours in circulation. Tedisamil is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents. Tedisamil also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered.
Tedisamil is manufactured by Solvay Pharmaceuticals Inc. under the proposed trade name Pulzium.